RandallAlanOyerMD

Oncology • Lancaster, PA

Physician

Join to view full profile

Dr. Oyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oyer's full profile

Already have an account?

Office
2102 Harrisburg Pike
Lancaster, PA 17604
Phone+1 717-544-7154

Fax+1 717-544-7153

Summary

I am a Medical Oncologist serving as the founding Medical Director of the Ann B. Barhshinger Cancer Institute Penn Medicine Lancaster General in Lancaster, Pennsylvania. I am active with ASCO and ACCC.

Education & Training

Drexel University College of Medicine/Hahnemann University HospitalFellowship, Hematology and Medical Oncology, 1984 - 1986
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1980 - 1984
Georgetown University School of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1992 - 2025
PA State Medical License 1982 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

70 citations
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research S...
Randall A Oyer, Patricia Hurley, Leigh Boehmer, Suanna Steeby Bruinooge, Kathryn Levit
Journal of Clinical Oncology. 2022-07-01
5 citations
Toward Predicting 30-Day Readmission Among Oncology Patients: Identifying Timely and Actionable Risk Factors.
Sy Hwang, Ryan Urbanowicz, Selah Lynch, Tawnya Vernon, Kellie Bresz
JCO Clinical Cancer Informatics. 2023-02-01
14 citations
Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Asses...
Carmen Guerra, Alice Pressman, Patricia Hurley, Elizabeth Garrett-Mayer, Suanna S Bruinooge
JCO Oncology Practice. 2023-04-01

Press Mentions

Extending the Reach of Proton TherapyMay 29th, 2024
Doctors See Both Setbacks, Advances in Breast Cancer CareOctober 4th, 2022
Rucaparib Is Effective in Maintenance Treatment for Ovarian CancerJune 8th, 2022
Join now to see all

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member